UCB Assessing Bepranemab’s Future After Roche/Genentech Ends Partnership

Tau-Targeting Collaboration Dated Back To 2020

 
• By Mandy Jackson
  
Phase IIa data in prodromal and mild Alzheimer's disease will be presented at CTAD (Shutterstock)

More from Deals

More from Scrip